Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
JAYPIRCA (PIRTOBRUTINIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
JAYPIRCA
NDA
Get alerts
PIRTOBRUTINIB | N216059 | LOXO ONCOLOGY INC
2 strengths
7 unique patents
5 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
Medicare D
Approvals
Label
Products
Patent Timeline
7 unique patents, 5 exclusivities by expiration date
All strengths
50MG
100MG
Active (7)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
Today
10342780
Dec. 16, 2036
10464905
Dec. 16, 2036
10695323
Dec. 16, 2036
10918622
Dec. 16, 2036
12109193
Sep. 14, 2041
12220401
Dec. 16, 2036
12268666
Jul. 29, 2039
NCE
Jan. 27, 2028
I-981
Dec. 2, 2028
ODE-424
Jan. 27, 2030
ODE-451
Dec. 1, 2030
ODE-518
Dec. 3, 2032
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 50MG
RLD
7 patents
5 exclusivities
▴
TABLET;ORAL | Approved: Jan 27, 2023
Patents (7)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10342780
Dec 16, 2036
—
Yes
Yes
—
—
10464905
Dec 16, 2036
—
—
—
U-3518
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR
—
10695323
Dec 16, 2036
—
Yes
Yes
U-3518
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR
—
10918622
Dec 16, 2036
—
—
—
U-3518
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR
—
12109193
Sep 14, 2041
—
—
Yes
—
—
12220401
Dec 16, 2036
—
Yes
Yes
U-3518
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR
—
12268666
Jul 29, 2039
—
—
Yes
—
—
Exclusivities (5)
Code
Date
Status
I-981
Dec 2, 2028
Active
NCE
Jan 27, 2028
Active
ODE-424
Jan 27, 2030
Active
ODE-451
Dec 1, 2030
Active
ODE-518
Dec 3, 2032
Active
#002 — 100MG
RLD
7 patents
5 exclusivities
▾
TABLET;ORAL | Approved: Jan 27, 2023